Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients
The primary purpose of the study is to investigate the safety and efficacy of KP-1461 given every 12 hours for 124 days to HIV+ patients who have failed multiple antiretroviral regimens.
- Trial name
- NCT00504452
- Testing
- KP-1461
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Koronis Pharmaceuticals.
HIV -1 Infection, Methamphetamine Use
Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in people with HIV (PWH) is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT07584369)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
HIV-1 Infection
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen…
- Trial name
- NCT02605954
- Testing
- E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
- Where
- 49 sites in United States, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or…
- Trial name
- FLAMINGO (NCT01449929)
- Testing
- dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
- Where
- 66 sites in United States, France and 7 more
- Volunteers
- 488 people
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications.
- Trial name
- NCT00002375
- Testing
- Indinavir sulfate, Nelfinavir mesylate
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients
Several studies from HIV-NAT have demonstrated high nevirapine, indinavir, saquinavir and lopinavir/r levels when compared to Caucasian patients.
- Trial name
- NCT00411957
- Testing
- Atazanavir
- Where
- Thailand
- Volunteers
- 22 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently…
- Trial name
- NCT00808002
- Testing
- Raltegravir, Maraviroc, Tenofovir/Emtricitabine
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infections
Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
- Trial name
- NCT00002066
- Testing
- Thymopentin
- Where
- United States
- Sponsor
- Immunobiology Research Institute
Hypertension, HIV-1-infection
Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression
Among those with hypertension, persons living with HIV (PWH) have a 50% higher risk of incident myocardial infarction compared to the general population, and they often fail to meet evidence-based treatment goals for…
- Trial name
- NCT05459077
- Testing
- Hypertension control through education and monitoring
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
HIV Infections
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
Development of tolerable and effective antiretroviral (ARV) drugs for use in children and adolescents remains a high priority. First-line therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs) has proven to be…
- Trial name
- NCT01975012
- Testing
- Rilpivirine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially
The primary object of the study is to assess the safety profile of candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04563377
- Testing
- ChAdOx1.HTI and MVA.HTI
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV Infections
A Study of 1592U89 in HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
- Trial name
- NCT00002200
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infection
CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)
The study aims to define and compare the immunological characteristics (lymphocyte subpopulations, specific immunity against HIV, lymphocyte activation, inflammatory parameters) and the virological characteristics (study of viral…
- Trial name
- CLEAC (NCT02674867)
- Testing
- Blood draw
- Where
- 11 sites in France
- Volunteers
- 80 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection, Pregnancy Related
Dolutegravir in Pregnant HIV Mothers and Their Neonates
To evaluate dolutegravir (DTG) efficacy in women who present with untreated HIV in late pregnancy. An open-label, multi-centre randomised controlled trial of DTG vs efavirenz-based regimens for women commencing cART in late…
- Trial name
- DolPHIN-2 (NCT03249181)
- Testing
- Dolutegravir, Standard of Care (EFV + 2 NRTI backbone)
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 268 people
- Sponsor
- University of Liverpool
HIV, Acquired Immunodeficiency Syndrome
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an…
- Conditions
- HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral
- Trial name
- NCT04983030
- Testing
- Ad26.Mos4.HIV, MVA-BN-HIV, PGT121
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boris Juelg, MD PhD
HIV Infections
A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
The purpose of this study is to compare the safety and effectiveness of 2 dosing schedules (once daily vs twice daily) of lamivudine (3TC) given with stavudine (d4T) and either indinavir (IDV) or nelfinavir (NFV) for 24 weeks.
- Trial name
- NCT00002442
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 12 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized…
- Trial name
- NCT00056641
- Testing
- tipranavir, ritonavir, saquinavir
- Where
- 109 sites in United States, Australia and 11 more
- Volunteers
- 328 people
- Sponsor
- Boehringer Ingelheim
Tuberculosis, Latent Tuberculosis Infection
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
The purpose of this study is to evaluate whether isoniazid can safely (and further) reduce the risk of tuberculosis in HIV infected people receiving HAART.
- Conditions
- Tuberculosis, Latent Tuberculosis Infection, HIV Infections
- Trial name
- HAART-IPT (NCT00463086)
- Testing
- isoniazid
- Where
- South Africa
- Volunteers
- 1,368 people
- Sponsor
- University of Cape Town
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
To determine the safety of and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration of antibody response and its relationship to the…
- Trial name
- NCT00001056
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen
To assess the safety, tolerance, and efficacy of amprenavir (APV) plus abacavir (ABC) in patients who have previously failed antiretroviral treatment containing a protease inhibitor (PI).
- Trial name
- NCT00002205
- Testing
- Abacavir sulfate, Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.